Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Eptinezumab as an Adjunct to Standard of Care for MIGRANE in an Acute EmeRgency Context (Migraine ERase Study)

NCT06428838 is registered in ClinicalTrials.gov with Dr George Medvedev as lead sponsor.

NCT NCT06428838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06428838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Eptinezumab as an Adjunct to Standard of Care for MIGRANE in an Acute EmeRgency Context (Migraine ERase Study)
Lead sponsor
Dr George Medvedev
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
May 5, 2025
Completion date
March 31, 2028
Enrollment
102 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic migraine, migraine